NCCN practice guidelines for Hodgkin's disease

Authors

Richard Hoppe, Stanford University, USA
Richard Abrams, University of Chicago, USA
Steven Bernstein, University of Rochester Medical Center, USA
Paul Bierman, University of Nebraska Medical Center, USA
Clara Bloomfield, The Ohio State University Comprehensive Cancer Center, USA
James Cox, The University of Texas MD Anderson Cancer Center, USA
Leo Gordon, Northwestern University Feinberg School of Medicine, USA
Sandra Horning, Stanford University, USA
Mark Kaminski, University of Michigan, USA

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

The National Comprehensive Cancer Network (NCCN) Practice Guidelines for Hodgkin's Disease provide a comprehensive framework for the diagnosis, treatment, and management of patients with Hodgkin's lymphoma. These guidelines, developed by a panel of experts including R. T. Hoppe, R. Abrams, S. Bernstein, P. Bierman, C. D. Bloomfield, J. Cox, L. Gordon, S. Horning, M. Kaminski, G. Love, T. Loughran, D. Maloney, P. Mauch, A. Molina, M. N. Saleh, R. Schilder, J. Winter, J. Yahalom, and A. Zelenetz, offer evidence-based recommendations that encompass all stages of Hodgkin's lymphoma. The guidelines address key aspects of patient care, including diagnostic workup, staging, risk stratification, and treatment options ranging from chemotherapy and radiotherapy to novel therapies like immunotherapy and targeted agents.

In particular, these guidelines highlight the importance of individualized treatment plans based on patient-specific factors such as age, disease stage, and comorbidities. They also emphasize the critical role of multidisciplinary teams in managing Hodgkin's disease, ensuring that patients receive optimal care through coordinated efforts among oncologists, radiologists, pathologists, and other healthcare professionals.

The NCCN guidelines also provide recommendations for follow-up care and monitoring for disease recurrence, as well as guidance on the management of long-term treatment-related toxicities. The guidelines serve as an essential resource for clinicians to standardize care, improve patient outcomes, and integrate the latest advances in the treatment of Hodgkin's lymphoma.

These guidelines are continually updated to reflect new research findings and evolving treatment paradigms, making them a vital tool in the clinical management of Hodgkin's disease.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Oncology

Recommended Citation

Hoppe, R., Abrams, R., Bernstein, S., Bierman, P., Bloomfield, C., Cox, J., Gordon, L., Horning, S., Kaminski, M. (1999). NCCN practice guidelines for Hodgkin's disease. Oncology, 13(5), 78-110.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/110